Edaravone administration in pivotal clinical Study 19

"Edaravone administration in pivotal clinical Study 19." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 20(3-4), pp. 298–299

View responses to this article:

Is edaravone harmful? (A placebo is not a control)

This article responds to:

Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin)

Acknowledgements

The authors thank p-value communications for editorial and medical writing assistance. p-value communications received funding from Mitsubishi Tanabe Pharma America, Inc., for their contributions.

Declaration of interest

Angela Genge is a consultant for Mitsubishi Tanabe Pharma America, AL-S Pharma, AveXis, Alexion, Alnylam Pharmaceuticals, Akcea Therapeutics, Biogen, AB Science, Roche, Novartis, Sanofi-Genzyme, UCB, and Brainstorm Cell Therapeutics. Benjamin Brooks is a consultant for Mitsubishi Tanabe Pharma America.

Additional information

Funding

This work was supported by Mitsubishi Tanabe Pharma America, Inc.